Send us a text

Monoclonal gammopathy of renal significance (MGRS) is a hemato-nephrological term referring to a heterogeneous group of kidney disorders characterized by direct or indirect kidney injury caused by a monoclonal immunoglobulin (MIg) produced by a B cell or plasma cell clone that does not meet current hematologic criteria for therapy. MGRS-associated kidney diseases are diverse and can result in the development of end stage kidney disease (ESKD).

In this episode we have the pleasure of having the Belgian Assistant professor Dr Amaryllis Van Craenenbroeck with us in the studio.  She is Assistant professor at UZ Leuven and specialises in kidney transplantation and kidney diseases.



MAT-BE-2301080 (ver.1) Oct 2023

Send us a text

Sickle cell disease (SCD) is a hereditary blood disorder, where red blood cells have the shape of a C or sickle - hence the name. Sickle cells have a shorter lifespan than normal red blood cells, which causes anemia. Additionally, sickle cells may block blood vessels, especially during infections, dehydration, stress or fatigue, causing complications for the patients.
 
Our guest today Professor Bart Biemond is a haematologist at the Amsterdam UMC in The Netherlands. Bart is head of the Hemoglobinopathy Expert Center and an active member of the medical advisory boards of the national patient associations. His efforts in research have led among others to greater understanding of biomarkers in SCD and complications associated with this disease. In this episode of our Haematology Podcast, Bart will tell us more about SCD, its clinical implications and developments in research which implicate patients today and in the future. 



MAT-BE-2300066 (ver.1) July 2023

Send us a text

Extramedullary disease (EMD) represents an aggressive form of multiple myeloma, characterized by the ability of myeloma cells to form tumors outside the bone marrow independently.  Scientific research is continuously evolving, leading to discoveries of new treatments and improvements to current options. However, EMD in myeloma remains challenging from a therapeutic and biological perspective, and today the prognosis for patients with the disease is generally poor. Experts call for a better understanding of how myeloma cells grow and thrive and the biology of extramedullary tumors in order to develop better treatment strategies for the future.

Guest in this episode is Dr. Elena Zamagni,  an associate professor at the Department of Medical and Surgical Sciences at the University of Bologna and has been a principal investigator in several national and international clinical trials in Multiple Myeloma.


MAT-BE-2300720  (ver.1) Jul 2023

Send us a text

Monoclonal gammopathy of undetermined significance, called MGUS, is a blood condition which indicates occurrence of clonal cells that secrete monoclonal immunoglobulins. MGUS as such, is not a harmful disease, and usually doesn’t require treatment. However, every year 1 percent of MGUS patients go on to develop myeloma or lymphoma. 

In this episode we have the pleasure of having the Icelandic Professor Sigurdur Kristinsson with us. He specialises in internal medicine and hematology. He has led several large population-based myeloma studies in collaboration with major research centers and is a frequent speaker at international hematology conferences. Professor Kristinsson will bring us up to date on recent understandings of the MGUS condition, what symptoms we as health care professionals should be aware of and how to diagnose today – and what could be possible in the future.


MAT-BE-2300364 (Ver. 1.0) 04 2023

Send us a text

Waldenström Macroglobulinemia is a rare type of non-Hodgkin lymphoma affecting B-cells. Waldenström Macroglobulinemia is characterised by high levels of circulating antibodies, immunoglobulin M, which is made and secreted by the cells involved in the disease. It is usually an indolent disease with no or limited symptoms. Therefore, patients with Waldenström Macroglobulinemia are often follow closely in “Watchful Waiting” until the disease and symptoms require onset of treatment. 

Our guest Ida Bruun Kristensen, haematologist at Odense University Hospital. Ida is an active member in both the Danish Lymphoma Group and Danish Myeloma Study Group as the active in the Nordic clinical societies and is responsible for several ongoing clinical studies. In this episode of our Haematology Podcast Ida enlighten us on Waldenström Macroglobulinemia, its clinical implications and treatment options for the patients today and in the future.

MAT-BE-2300296 04 2023

Send us a text

Mental health includes our emotional, psychological and social well-being. A physical illness can have a severe impact on mental health. As health care professionals we often focus primarily on treatment and how to handle side effects and complications. The mental aspect of a disease is taking the back seat. How is mental health affected by a cancer diagnosis and treatment. And what does mental health mean for the patient's ability to cope with treatment and for the final outcome of treatment? And how is mental health affected after treatment is completed? 
In this episode we have the pleasure of having  Professor Christoffer Johansen with us. He currently works at the Department of Oncology, Rigshospitalet in Denmark. Besides doing research in Oncology, Epidemiology and Clinical Trials, he has scientific focus on mental health for many years.
 

MAT-BE-2200987 (ver. 1.0) 12 2022

Send us a text

In this episode we will discuss rare, inherited metabolic disorders in general, as well diseases such as Gaucher and other diseases. These genetic conditions are very rare. They can be diagnosed, after suspicion, by different screening test. But symptoms may vary greatly within these disorders and the road to an accurate diagnosis can therefore be challenging.
Guest in this episode is Professor Allan Lund. He is a board-certified specialist in pediatrics with expert training in rare pediatric metabolism. He currently works at Rigshospitalet in Copenhagen Denmark where he is the leader of Center for Rare metabolic diseases for children and adults. He has spent several years of research, diagnosing, and treating patients with different rare metabolic disorders.

MAT-BE-2200986 (ver. 1.0) 12 2022

Send us a text

Hemoglobinopathies have previously been rare in the Nordic population but with increasing migration we now meet many patients with different types of thalassemias and hemoglobin variants. It is important to recognize these conditions and diagnosis can sometimes be challenging. In this episode  we will meet an expert in hemoglobin disorders who will discuss classification and diagnostic procedures. Britta Landin is associate professor and senior consultant at the Karolinska University Hospital in Stockholm. Host for the podcast is the Swedish hematologist Mats Merup. 

MAT-BE-2200985 (1.0) 12 2022

Send us a text

Minimal residual disease (MRD) can today be evaluated in individual patient after treatment using various methods with high sensitivity. MRD indicates remaining malignant cells that could be a source of relapse of the disease. Could MRD also be used as an efficient endpoint in the design of new clinical studies?  With help from Professor Ola Landgren, we will look into the crystal ball and discover what the future may hold for MRD.

Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Ola Landgren, Professor of Medicine, Chief of Myeloma Program & Experimental Therapeutics Program. Sylvester Comprehensive Cancer Center, University of Miami

MAT-BE-2200984 (1.0) 12 2022

Send us a text

Detection of Minimal Residual Disease (MRD) is  becoming more important in different fields of hematology including Multiple Myeloma. Over the past decades we’ve been able to improve the sensitivity of detecting minimal levels of MRD through innovations in molecular biology. But should MRD always be treated?  Will it give a better outcome for the patient? And do the benefits outweigh the costs?”

Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Dr Fredrik Schjesvold, head of the Oslo Myeloma Center.

MAT-BE-2200983 (1.0) 12 2022